BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30912007)

  • 1. Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients.
    Ali Beg MM; Fahdil SR; Yadav P; Shukla KK; Mohan A; Saxena A
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):825-830. PubMed ID: 30912007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
    Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study.
    Masroor M; Amit J; Javid J; Mir R; Prasant Y; Imtiyaz A; Mariyam Z; Mohan A; Ray PC; Saxena A
    Asian Pac J Cancer Prev; 2015; 16(17):7529-34. PubMed ID: 26625757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Polymorphisms in Activating Transcription Factor 3 Binding Site and the Prognosis of Early-Stage Non-Small Cell Lung Cancer.
    Kang HG; Park JE; Lee SY; Choi JE; Do SK; Hong MJ; Lee JH; Jeong JY; Do YW; Lee EB; Shin KM; Lee WK; Choi SH; Lee YH; Seo HW; Yoo SS; Lee J; Cha SI; Kim CH; Cho S; Jheon S; Park JY
    Oncology; 2021; 99(5):336-344. PubMed ID: 33626541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.
    Mohan A; Ansari A; Masroor M; Saxena A; Pandey RM; Upadhyay A; Luthra K; Khilnani GC; Jain D; Kumar R; Guleria R
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3153-3163. PubMed ID: 33247670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Impacts of
    Lee KL; Lai TC; Wang YC; Shih PC; Yang YC; Tsao TC; Liu TC; Wen YC; Chang LC; Yang SF; Chien MH
    Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33802737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases.
    Masroor M; Mir R; Javid J; Prasant Y; Imtiyaz A; Mariyam Z; Mohan A; Ray PC; Saxena A
    Asian Pac J Cancer Prev; 2015; 16(15):6445-9. PubMed ID: 26434857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer.
    Javid J; Mir R; Mirza M; Imtiyaz A; Prasant Y; Mariyam Z; Julka PK; Mohan A; Lone M; Ray PC; Saxena A
    Clin Transl Oncol; 2015 Apr; 17(4):289-95. PubMed ID: 25257838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
    Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
    Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations.
    Lee HW; Park YS; Park S; Lee CH
    Sci Rep; 2020 Sep; 10(1):14933. PubMed ID: 32913267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients.
    Masroor M; Jain A; Javid J; Mir R; Prashant Y; Imtiyaz A; Mariyam Z; Mohan A; Ray PC; Saxena A
    Asian Pac J Cancer Prev; 2015; 16(17):7653-8. PubMed ID: 26625776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
    Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
    Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.
    Singh A; Singh N; Behera D; Sharma S
    Pathol Oncol Res; 2019 Oct; 25(4):1327-1340. PubMed ID: 29209987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study.
    Mirza M; Javid J; Yadav P; Mohan A; Ray PC; Saxena A
    Ann Transl Med; 2016 Jun; 4(11):209. PubMed ID: 27386483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years.
    Xia J; Li H; Ji Y; Mi C; Chen G; Li P; Zhang R; Chen W; Wang J
    Curr Probl Cancer; 2019 Aug; 43(4):363-370. PubMed ID: 30522775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients.
    Masroor M; Javid J; Mir R; Y P; A I; Z M; Mohan A; Ray PC; Saxena A
    Tumour Biol; 2016 Jan; 37(1):857-63. PubMed ID: 26254096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
    Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
    Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.